Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)
Abstract Background Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. Method The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. Results The expert guidelines combine scientific evidence and expert clinician’s opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. Conclusion These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
BMC Psychiatry - 19(2019), 1, Seite 9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
D. Bennabi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anxiety disorders |
|---|
| doi: |
10.1186/s12888-019-2025-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ075792125 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ075792125 | ||
| 003 | DE-627 | ||
| 005 | 20230503085004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12888-019-2025-7 |2 doi | |
| 035 | |a (DE-627)DOAJ075792125 | ||
| 035 | |a (DE-599)DOAJ061f1b2374cf42b0a12e8c55d4f038fb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC435-571 | |
| 100 | 0 | |a D. Bennabi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. Method The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. Results The expert guidelines combine scientific evidence and expert clinician’s opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. Conclusion These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions. | ||
| 650 | 4 | |a Major depressive disorder | |
| 650 | 4 | |a Anxiety disorders | |
| 650 | 4 | |a Substance use disorders | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Pharmacotherapy | |
| 653 | 0 | |a Psychiatry | |
| 700 | 0 | |a A. Yrondi |e verfasserin |4 aut | |
| 700 | 0 | |a T. Charpeaud |e verfasserin |4 aut | |
| 700 | 0 | |a J.-B. Genty |e verfasserin |4 aut | |
| 700 | 0 | |a S. Destouches |e verfasserin |4 aut | |
| 700 | 0 | |a S. Lancrenon |e verfasserin |4 aut | |
| 700 | 0 | |a N. Allaili |e verfasserin |4 aut | |
| 700 | 0 | |a F. Bellivier |e verfasserin |4 aut | |
| 700 | 0 | |a T. Bougerol |e verfasserin |4 aut | |
| 700 | 0 | |a V. Camus |e verfasserin |4 aut | |
| 700 | 0 | |a O. Doumy |e verfasserin |4 aut | |
| 700 | 0 | |a J.-M. Dorey |e verfasserin |4 aut | |
| 700 | 0 | |a F. Haesebaert |e verfasserin |4 aut | |
| 700 | 0 | |a J. Holtzmann |e verfasserin |4 aut | |
| 700 | 0 | |a C. Lançon |e verfasserin |4 aut | |
| 700 | 0 | |a M. Lefebvre |e verfasserin |4 aut | |
| 700 | 0 | |a F. Moliere |e verfasserin |4 aut | |
| 700 | 0 | |a I. Nieto |e verfasserin |4 aut | |
| 700 | 0 | |a C. Rabu |e verfasserin |4 aut | |
| 700 | 0 | |a R. Richieri |e verfasserin |4 aut | |
| 700 | 0 | |a L. Schmitt |e verfasserin |4 aut | |
| 700 | 0 | |a F. Stephan |e verfasserin |4 aut | |
| 700 | 0 | |a G. Vaiva |e verfasserin |4 aut | |
| 700 | 0 | |a M. Walter |e verfasserin |4 aut | |
| 700 | 0 | |a M. Leboyer |e verfasserin |4 aut | |
| 700 | 0 | |a W. El-Hage |e verfasserin |4 aut | |
| 700 | 0 | |a B. Aouizerate |e verfasserin |4 aut | |
| 700 | 0 | |a E. Haffen |e verfasserin |4 aut | |
| 700 | 0 | |a P.-M. Llorca |e verfasserin |4 aut | |
| 700 | 0 | |a P. Courtet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t BMC Psychiatry |d BMC, 2003 |g 19(2019), 1, Seite 9 |w (DE-627)DOAJ000049468 |x 1471244X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:1 |g pages:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12888-019-2025-7 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/061f1b2374cf42b0a12e8c55d4f038fb |z kostenfrei |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1186/s12888-019-2025-7 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1471-244X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 1 |h 9 | ||